Evidence map›Paper›PMID 42327541›Full record

ReviewCurrent research in toxicology2026

Research on the safety risk of oral nicotine products and its prospects.

YanLing Yang, Huan Liang, Yi Liu, Qi Zhang

Abstract readReview
In one paragraph

Review in Current research in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

YanLing YangDepartment of Pharmacy, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, 445000, China.
Huan LiangDepartment of Obstetrics and Gynaecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, 445000, China.
Yi LiuWuHan University, WuHan, Hubei, 430070, China.
Qi ZhangHubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral nicotine products are a category of novel tobacco products that deliver nicotine through oral consumption. With increasing tobacco control measures worldwide and growing public health awareness, its safety risk has gained attention. However, the regulatory authorities still lack long-term data for oral nicotine products and limited data on additives, so the continued in-depth research is required in the future. By integrating data from chemical analyses, animal/cell studies, and human cohorts, this review first introduces the main commercially available oral nicotine products and their classifications, analyzes the potentially harmful substances and their concentrations, and then systematically elucidates the health effects of oral nicotine products (including on oral and cardiovascular systems) and their underlying mechanisms. Finally, based on relevant research, it proposes future directions for safety risk studies on oral nicotine products. In summary, this review offers consumers a clearer understanding of the safety risks of oral nicotine products, provides evidence to support their rational use, and delivers insights for companies and regulators to develop effective policies and reduce health risks.

Indexed as

Health risksOral nicotine productsPopulation studiesPublic healthSafety risk assessment

Identifiers

PMID42327541
PMCPMC13279749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.